Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) said its new powder formulation of trofinetide, marketed as DAYBUE STIX, is now available in the United States for the treatment of Rett syndrome. The U.S.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and ...

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal ...

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million ...

Charles R. Goulding and Andressa Bonafe highlight the shift from clinical pilot programs to everyday pharmacy practice, where ...

Research presented at NAPNAP 2026 discusses the rising popularity of herbal supplements among children and adolescents.

Spread the loveOn March 30, 2026, Nestlé unveiled its latest innovation, the Compleat Paediatric Nutritional Blend, designed specifically to meet the unique nutritional requirements of children with ...

The $600,000 AICE-funded project represents a significant contribution toward the overall cost of the Phase I clinical trial of MB-204 and supports the advancement of the program into human trials.

Researchers in Thessaloniki introduced a breakthrough in paediatric medication, using 3D printing and powdered infant milk to create chewable, ...

Independent oversight reinforces manufacturing, supply chain integrity, and federal readiness for a platform designed to scale across multiple ...